Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,003 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetics of a Single Oral Dose of the MEK1/2 Inhibitor Selumetinib in Subjects With End-Stage Renal Disease or Varying Degrees of Hepatic Impairment Compared With Healthy Subjects.
Dymond AW, Martin P, So K, Huang Y, Severin P, Holmes V, Mariani G, Marbury T. Dymond AW, et al. Among authors: mariani g. J Clin Pharmacol. 2017 May;57(5):592-605. doi: 10.1002/jcph.848. Epub 2016 Dec 26. J Clin Pharmacol. 2017. PMID: 28019010 Free PMC article. Clinical Trial.
Evaluation of the Effect of Selumetinib on Cardiac Repolarization: A Randomized, Placebo- and Positive-controlled Crossover QT/QTc Study in Healthy Subjects.
Zhou D, So K, Dymond AW, Vik T, Al-Huniti N, Mariani G, Zorenyi G, Huang Y, Holmes V, Severin P, Rasmussen S, Martin P. Zhou D, et al. Among authors: mariani g. Clin Ther. 2016 Dec;38(12):2555-2566. doi: 10.1016/j.clinthera.2016.10.004. Epub 2016 Nov 9. Clin Ther. 2016. PMID: 27837934 Free article. Clinical Trial.
Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and induction on the exposure of selumetinib, a MEK1/2 inhibitor, in healthy subjects: results from two clinical trials.
Dymond AW, So K, Martin P, Huang Y, Severin P, Mathews D, Lisbon E, Mariani G. Dymond AW, et al. Among authors: mariani g. Eur J Clin Pharmacol. 2017 Feb;73(2):175-184. doi: 10.1007/s00228-016-2153-7. Epub 2016 Nov 26. Eur J Clin Pharmacol. 2017. PMID: 27889832 Free PMC article. Clinical Trial.
Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT).
Carvajal RD, Piperno-Neumann S, Kapiteijn E, Chapman PB, Frank S, Joshua AM, Piulats JM, Wolter P, Cocquyt V, Chmielowski B, Evans TRJ, Gastaud L, Linette G, Berking C, Schachter J, Rodrigues MJ, Shoushtari AN, Clemett D, Ghiorghiu D, Mariani G, Spratt S, Lovick S, Barker P, Kilgour E, Lai Z, Schwartz GK, Nathan P. Carvajal RD, et al. Among authors: mariani g. J Clin Oncol. 2018 Apr 20;36(12):1232-1239. doi: 10.1200/JCO.2017.74.1090. Epub 2018 Mar 12. J Clin Oncol. 2018. PMID: 29528792 Free article. Clinical Trial.
Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial.
Jänne PA, van den Heuvel MM, Barlesi F, Cobo M, Mazieres J, Crinò L, Orlov S, Blackhall F, Wolf J, Garrido P, Poltoratskiy A, Mariani G, Ghiorghiu D, Kilgour E, Smith P, Kohlmann A, Carlile DJ, Lawrence D, Bowen K, Vansteenkiste J. Jänne PA, et al. Among authors: mariani g. JAMA. 2017 May 9;317(18):1844-1853. doi: 10.1001/jama.2017.3438. JAMA. 2017. PMID: 28492898 Free PMC article. Clinical Trial.
Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells.
Vonderheide RH, LoRusso PM, Khalil M, Gartner EM, Khaira D, Soulieres D, Dorazio P, Trosko JA, Rüter J, Mariani GL, Usari T, Domchek SM. Vonderheide RH, et al. Clin Cancer Res. 2010 Jul 1;16(13):3485-94. doi: 10.1158/1078-0432.CCR-10-0505. Epub 2010 May 17. Clin Cancer Res. 2010. PMID: 20479064 Clinical Trial.
High dose-intensity chemotherapy, with accelerated cyclophosphamide-doxorubicin-etoposide and granulocyte-macrophage colony stimulating factor, in the treatment of small cell lung cancer.
Ardizzoni A, Venturini M, Crinò L, Sertoli MR, Bruzzi P, Pennucci MC, Mariani GL, Garrone O, Bracarda S, Rosso R, et al. Ardizzoni A, et al. Among authors: mariani gl. Eur J Cancer. 1993;29A(5):687-92. doi: 10.1016/s0959-8049(05)80347-8. Eur J Cancer. 1993. PMID: 8385970
1,003 results